- Home
- REX vs GPCR Comparison
REX vs GPCR Comparison
Compare REX & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- GPCR
- Stock Information
- Founded
- REX 1980
- GPCR 2016
- Country
- REX United States
- GPCR United States
- Employees
- REX N/A
- GPCR N/A
- Industry
- REX Major Chemicals
- GPCR
- Sector
- REX Industrials
- GPCR
- Exchange
- REX Nasdaq
- GPCR Nasdaq
- Market Cap
- REX 1.1B
- GPCR 1.2B
- IPO Year
- REX N/A
- GPCR 2023
- Fundamental
- Price
- REX $32.43
- GPCR $34.50
- Analyst Decision
- REX Strong Buy
- GPCR Strong Buy
- Analyst Count
- REX 1
- GPCR 8
- Target Price
- REX $25.00
- GPCR $69.57
- AVG Volume (30 Days)
- REX 146.2K
- GPCR 1.2M
- Earning Date
- REX 12-04-2025
- GPCR 11-06-2025
- Dividend Yield
- REX N/A
- GPCR N/A
- EPS Growth
- REX N/A
- GPCR N/A
- EPS
- REX 1.49
- GPCR N/A
- Revenue
- REX $650,008,000.00
- GPCR N/A
- Revenue This Year
- REX $3.27
- GPCR N/A
- Revenue Next Year
- REX $17.11
- GPCR N/A
- P/E Ratio
- REX $21.67
- GPCR N/A
- Revenue Growth
- REX N/A
- GPCR N/A
- 52 Week Low
- REX $16.73
- GPCR $13.22
- 52 Week High
- REX $33.97
- GPCR $40.29
- Technical
- Relative Strength Index (RSI)
- REX 48.36
- GPCR 55.14
- Support Level
- REX $31.23
- GPCR $33.36
- Resistance Level
- REX $32.88
- GPCR $35.62
- Average True Range (ATR)
- REX 1.07
- GPCR 2.38
- MACD
- REX 0.14
- GPCR -0.28
- Stochastic Oscillator
- REX 50.25
- GPCR 39.62
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.